Page 157 - நாஸ்டாக் உலகளாவிய தேர்ந்தெடுக்கவும் சந்தை News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced the closing of its merger with Sunesis Pharmaceuticals, Inc. (previously trading on Nasdaq under "SNSS"). The combined, publicly traded company will focus on the advancement and expansion of Viracta's clinical stage pipeline, including Viracta's lead program for the treatment of Epstein-Barr virus (EBV)-positive lymphoma. Shares of the combined company, which is operating under the name Viracta Therapeutics, Inc., will commence trading on the Nasdaq Global Select Market under the ticker symbol "VIRX" on February 25, 2021.

Nasdaq global select marketSunesis pharmaceuticalsClinical trialIvor roystonClinical stageCombined companyViracta therapeuticsPrivate placementPrecision oncologyEpstein barr virusநாஸ்டாக் உலகளாவிய தேர்ந்தெடுக்கவும் சந்தைமருத்துவ சோதனைஐவர் ராய்ஸ்டன்மருத்துவ நிலைஒருங்கிணைந்த நிறுவனம்ப்ரைவேட் வேலை வாய்ப்பு